ADTX News and Press, ADiTx Therapeutics Inc. From 05/25/22

Data from the National Organization for Rare Disorders shows that roughly one to two individuals out of every 100,000 globally are diagnosed with autoimmune hepatitis annually.  This rare liver disorder is characterized by an autoimmune response against healthy cells in the liver, whi...

Aditxt recently entered a multi-year partnership with GRS for the promotion of its proprietary AditxtScore Immune Monitoring Platform Aditxt plans to roll out the monitoring platform to medical offices, pharmacies, laboratories, and employers across the country, with promotion through n...

Aditxt is commercializing new innovations with focus on mapping and reprogramming the immune system Aditxt is actively adding distribution channel partners for AditxtScore(TM) throughout the U.S. and globally The company aims to expand reimbursement coverage for AditxtScore(TM) for CO...

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse G...

3 Penny Stocks For Your Watchlist After a Bearish Trading Day There’s a lot of debate surrounding penny stocks – whether they’re actually worth investing in, or if they’re just an easy way to make quick money. So, what’s the verdict? Are penny stocks...

Penny stocks are at the top of the minds of thousands of investors in the stock market today. Even with broader markets trading lower ahead of tomorrow’s Fed minutes, traders are looking to capitalize on the wild volatility that has come into play. One of the areas of the penny stock...

Aditxt (NASDAQ:ADTX) said it signed a revenue-sharing agreement with Cellvera, formerly AiPharma Global Holdings, which is being acquired by the company. The company said Cellvera, holds exclusive worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting...

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security ...

Presented by Maxim Group LLC and Hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO &a...

Aditxt meets the timeline imposed by the FDA for laboratory-developed tests (“LDT”s) to request Emergency Use Authorization (“EUA”) by January 14 th AditxtScore™ for COVID-19 will continue to be available during the FDA review A...